Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004) (NCT06726265)
TACTI-004, a Double-Blinded, Randomized Phase 3 Trial in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Receiving Eftilagimod Alfa (MHC Class II Agonist) in Combination With Pembrolizumab (PD-1 Antagonist) and Chemotherapy.
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to compare eftilagimod alfa (efti) in combination with pembrolizumab and chemotherapy versus placebo in combination with pembrolizumab and chemotherapy with respect to overall survival (OS) and progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) among adults with metastatic non-small cell lung cancer (NSCLC). Participants will receive either efti plus standard treatment (pembrolizumab and platinum doublet chemotherapy) or placebo plus standard treatment and will be treated for up to 2 years.
Who can join: Review the eligibility criteria below.
Location: Norton Cancer Institute - Audubon — Louisville, Kentucky
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (147 Sites)
Showing the first 25 of 147 sites.
- Norton Cancer Institute - Audubon — Louisville, Kentucky
- New Mexico Oncology Hematology Consultants, Ltd. — Albuquerque, New Mexico
- Ascension Seton Infusion Center — Austin, Texas
- Centro de Endocrinologia y Diabetes Dr. Raul A. Gutman SRL — Buenos Aires,
- Fundacion Respirar — Buenos Aires,
- Hospital Británico de Buenos Aires — Buenos Aires,
- Sanatorio Parque - Rosario — Rosario,
- Clinica Viedma — Viedma,
- Lyell McEwin Hospital — Elizabeth Vale,
- Greenslopes Private Hospital — Greenslopes,
- The Alfred Hospital — Melbourne,
- Tasman Oncology Research Ltd — Southport,
- St John of God Subiaco Hospital — Subiaco,
- Royal Darwin Hospital — Tiwi,
- Calvary Mater Newcastle — Waratah,
- Cancer Care Wollongong Pty Limited — Wollongong,
- Landeskrankenhaus-Universitätsklinikum Graz, KLinische Abteilung für Pulmonologie — Graz,
- Vienna General Hospital — Vienna,
- Antwerp University Hospital — Antwerp,
- Algemeen Ziekenhuis Maria Middelares — Ghent,
- Clinique et Maternité Sainte-Elisabeth — Namur,
- Universidade de Caxias do Sul — Caxias do Sul,
- Centro Integrado de Oncologia de Curitiba - CIONC — Curitiba,
- Cetus Oncologia Hospital Dia - Belo Horizonte — Horizonte,
- Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda — Ijuí,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Explore by condition: All Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.